HIV 101: Foundations of Management of People Who Are Newly Diagnosed With HIV (On-Demand)

HIV 101: Foundations of Management of People Who Are Newly Diagnosed With HIV (On-Demand)

Presenters: Michael S. Saag, MD, Carolyn Chu, MD, MSc, and Roy M. Gulick, MD, MPH

Release date: September 25, 2025
Expiration date: September 25, 2026
CME Credit Available: 1.5 AMA PRA Category 1 Credits

Additional Information

Overview

Assessment of Needs

A firm grasp of the basics of clinical care for patients with HIV is essential for practitioners in Ryan White HIV/AIDS-funded clinics and programs who are new to HIV care. In this webinar, experts in the field described the core principles of HIV management, including pathogenesis of HIV infection and mechanisms of action of antiretroviral drugs, as well as initiating antiretroviral therapy and primary care for people who are newly diagnosed with HIV. This webinar is also useful to experienced clinicians who seek a review of these core principles.

Learning Objectives

HIV 101: Fundamentals of HIV Pathogenesis, Antiretroviral Therapy, and Drug Resistance
Presenter: Michael S. Saag, MD
University of Alabama at Birmingham

Learning Objectives
On completion of this activity, learners will be able to:

  • Describe the pathogenesis of HIV disease and the life cycle of HIV
  • Describe how to use knowledge of the pathogenesis of HIV in clinical practice
  • Describe the basic mechanisms of drug resistance

HIV 101: Primary Care for People Newly Diagnosed With HIV
Presenter: Carolyn Chu, MD, MSc
University of California San Francisco

Learning Objectives
On completion of this activity, learners will be able to:

  • Conduct an initial assessment of a person newly diagnosed with HIV, including conducting a patient history, ordering appropriate tests, and devising a plan to ensure engagement in care
  • Describe the timing of appropriate vaccinations for people newly diagnosed with HIV
  • Describe how to provide continuous monitoring for antiretroviral therapy success and for the emergence of comorbid conditions, including cardiovascular disease, renal disease, frailty, and other clinical presentations

HIV 101: Initiation of Antiretroviral Therapy
Presenter: Roy M. Gulick, MD, MPH
Weill Cornell Medicine
New York, NY

Learning Objectives
On completion of this activity, learners will be able to:

  • Initiate an appropriate antiretroviral therapy (ART) regimen in a person newly diagnosed with HIV according to their clinical presentation and preference
  • Describe the concept of drug resistance testing and its role in maintaining appropriate ART regimens
  • Describe appropriate ART regimens for special populations

Registration

Who Should Attend

This program is designed for clinical decision-makers in Ryan White HIV/AIDS Program (RWHAP)-funded clinics and programs who are new to HIV care and those practitioners who are interested in a review. It is also relevant for registered nurses, pharmacists, and other health care professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA has identified and mitigated ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter/Planner

Dr Saag reported no financial relationships with ineligible companies. (Updated September 10, 2025)

Presenters

Dr Gulick reported no relevant financial relationships with ineligible companies. (Updated September 10, 2025)

Dr Chu reported no relevant financial relationships with ineligible companies. (Updated September 6, 2025)

Planners/Reviewers

Planners/Reviewers 1 and 2 reported no relevant financial relationships with ineligible companies. (Updated August 25, 2025)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/ 

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

Platinum Supporters

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.

Course Materials

How to Claim Credit

  1. Start the Activity by clicking "START COURSE" located above.
    Please note that the "START COURSE" will no longer be visible once you clicked it once.
  2. Watch the webinar here.
  3. Return to this page and follow this link to the evaluation form.
  4. Once you complete the evaluation, you will be directed to the online claim form, where you will record the number of hours that you participated in this activity. You must be logged in to your IAS–USA profile to claim credit. Please note: if you already have participated in the live webinar and have received CME credit, you will not receive additional credit from this activity.
  5. Your certificate will be available for you to print from your IAS–USA account immediately after you have submitted your claim form. To view your certificates, go to "My Activities" under your profile.

You must be logged in to access this course.